Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Valiglurax (VU2957), also known as VU0652957 and VU2957, is a potent, selective, CNS penetrant, and orally bioavailable mGlu4 PAM. VU2957 possessed attractive in vitro and in vivo pharmacological and DMPK properties across species. VU2957 was evaluated as a preclinical development candidate for the treatment of Parkinson’s disease.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
1 mg | 在庫あり | ¥ 7,500 | |||
5 mg | 在庫あり | ¥ 16,500 | |||
10 mg | 在庫あり | ¥ 28,000 | |||
25 mg | 在庫あり | ¥ 60,500 | |||
50 mg | 在庫あり | ¥ 103,000 | |||
100 mg | 在庫あり | ¥ 153,000 | |||
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 18,500 |
説明 | Valiglurax (VU2957), also known as VU0652957 and VU2957, is a potent, selective, CNS penetrant, and orally bioavailable mGlu4 PAM. VU2957 possessed attractive in vitro and in vivo pharmacological and DMPK properties across species. VU2957 was evaluated as a preclinical development candidate for the treatment of Parkinson’s disease. |
In vivo | Valiglurax (0.3-30 mg/kg; po) reversed haloperidol-induced catalepsy (HIC) in rats[1]. |
別名 | VU2957, VU 0652957, VU 2957, VU-0652957, VU0652957, VU-2957 |
分子量 | 329.28 |
分子式 | C16H10F3N5 |
CAS No. | 1976050-09-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 112.5 mg/mL (341.7 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Valiglurax 1976050-09-5 Neuroscience GluR VU2957 VU 0652957 VU 2957 VU-0652957 VU0652957 VU-2957 Inhibitor inhibitor inhibit